Our COVID-19 Research

Information on our COVID-19 Research

COVID-19 News

Moderna's COVID-19 booster vaccine trial targeting the Omicron Variant

Moderna is conducting a clinical trial, called the mRNA-1273-P305 clinical trial, on an investigational booster vaccine that may protect against the COVID-19 Omicron variant, and you may be eligible to take part. The mRNA-1273-P305 clinical trial is evaluating the safety and immune response of the investigational mRNA-1273.529 booster vaccine compared to a booster dose of Moderna’s COVID-19 vaccine, Spikevax.

This trial is enrolling volunteers 16 years of age or older who are in good or stable health and have received two or three doses of the COVID-19 vaccine at least three months ago.

Participation in this trial lasts up to 13 months and includes phone calls and approximately 5-7 scheduled visits to the trial site. Participants will receive a single dose of either investigational booster vaccine, mRNA-1273.529, or the already authorized vaccine, Spikevax.

To learn more, please visit https://connect.trialscope.com/studies/0a9015ce-4de7-49a8-8683-a2f5fe6fa455

(February 2022)

Sheffield Teaching Hospitals shortlisted for award for pioneering role in Oxford vaccine development

Clinical research teams at Sheffield Teaching Hospitals NHS Foundation Trust have been shortlisted for a British Medical Journal (BMJ) award for their leading role in the research behind the development of the Oxford Vaccine.

The team have been put forward for the prestigious award as part of collective group of all of the study sites in the UK which were involved in the development of the vaccine. The nomination is for the clinical leadership category, which recognises a team that exemplifies the qualities of clinical leadership, requiring ideas and enthusiasm and often by doing things differently.

You can read more about this on the Sheffield Teaching Hospitals News Page

(October 2021)

Longer interval between the first and second Pfizer vaccine boosts antibody levels and ‘helper’ T cells

A new study supported by the CRF, which published today (23 July) as a pre-print on ‘Cell Press Sneak Peak’, by the Universities of Sheffield, Oxford, Liverpool, Newcastle, and Birmingham, with support from the UK Coronavirus Immunology Consortium, shows both short and long dosing schedules of the Pfizer Covid-19 vaccine generate strong antibody and T cell immune responses.

Please read more on the Sheffield Teaching Hospitals News Page

(July 2021)

2020: A year to remember at NIHR Sheffield CRF

Photo of team on an MS Teams Call

The impact of the COVID-19 pandemic has been felt across the NHS and research infrastructure like nothing else in the lifetime of Clinical Research Facilities (CRF).

Whilst we can see and appreciate the struggles and challenges the last 12 months have brought, now is surely the time to celebrate the achievements and triumphs of the research infrastructure. We look forward to a time when we can reflect on how adaptations that we have made could be for the better.

The NIHR Sheffield CRF would like to take an opportunity to share some of the adaptations we have made in a time when there has never been more awareness of clinical research thanks to advancements that we have contributed to with unprecedented speed.

Please read more in our blog on the UKCRF Network website

(March 2021)